Literature DB >> 24882804

IL-32γ induces chemotaxis of activated T cells via dendritic cell-derived CCL5.

Mi Hye Son1, Mi Young Jung1, Seulah Choi1, Daeho Cho2, Tae Sung Kim3.   

Abstract

Interleukin (IL)-32 has been associated with a variety of inflammatory diseases including rheumatoid arthritis, vasculitis and Crohn's disease. We have previously reported that IL-32γ, the IL-32 isoform with the highest biological activity, could act as an immune modulator through regulation of dendritic cell (DC) functions in immune responses. Cell locomotion is crucial for induction of an effective immune response. In this study, we investigated the effect and underlying mechanisms of IL-32γ on recruitment of T cells. IL-32γ upregulated the expression of several chemokines including CCL2, CCL4, and CCL5 in the DCs. In particular, IL-32γ significantly increased CCL5 expression in a dose-dependent manner. Treatment with JNK and NF-κB inhibitors suppressed IL-32γ-induced CCL5 expression in DCs, indicating that IL-32γ induced CCL5 production through the JNK and NF-κB pathways. Furthermore, supernatants from IL-32γ-treated DCs showed chemotactic activities controlling migration of activated CD4(+) and CD8(+) T cells, and these activities were suppressed by addition of neutralizing anti-CCL5 antibody. These results show that IL-32γ effectively promotes migration of activated T cells via CCL5 production in DCs. The chemotactic potential of IL-32γ may explain the pro-inflammatory effects of IL-32 and the pathologic role of IL-32 in immune disorders such as rheumatoid arthritis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Activated T cells; CCL5; Chemotaxis; Dendritic cells; IL-32

Mesh:

Substances:

Year:  2014        PMID: 24882804     DOI: 10.1016/j.bbrc.2014.05.052

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Genome-Wide DNA Methylation Profiling in CD8 T-Cells and Gamma Delta T-Cells of Asian Indian Patients With Takayasu Arteritis.

Authors:  Jayakanthan Kabeerdoss; Debashish Danda; Ruchika Goel; Hindhumathi Mohan; Sumita Danda; R Hal Scofield
Journal:  Front Cell Dev Biol       Date:  2022-06-23

Review 2.  Cytokine-modulating strategies and newer cytokine targets for arthritis therapy.

Authors:  Shivaprasad H Venkatesha; Steven Dudics; Bodhraj Acharya; Kamal D Moudgil
Journal:  Int J Mol Sci       Date:  2014-12-31       Impact factor: 5.923

3.  De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.

Authors:  Matheus Rodrigues Lopes; João Kleber Novais Pereira; Paula de Melo Campos; João Agostinho Machado-Neto; Fabiola Traina; Sara T Olalla Saad; Patricia Favaro
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

Review 4.  The Biology and Role of Interleukin-32 in Tuberculosis.

Authors:  Wu Li; Wanyan Deng; Jianping Xie
Journal:  J Immunol Res       Date:  2018-10-22       Impact factor: 4.818

Review 5.  Type 1 Diabetes: Interferons and the Aftermath of Pancreatic Beta-Cell Enteroviral Infection.

Authors:  Pouria Akhbari; Sarah J Richardson; Noel G Morgan
Journal:  Microorganisms       Date:  2020-09-15

6.  Comparison of the Seven Interleukin-32 Isoforms' Biological Activities: IL-32θ Possesses the Most Dominant Biological Activity.

Authors:  Saerok Shim; Siyoung Lee; Yasmin Hisham; Sinae Kim; Tam T Nguyen; Afeisha S Taitt; Jihyeong Hwang; Hyunjhung Jhun; Ho-Young Park; Youngmin Lee; Su Cheong Yeom; Sang-Yeob Kim; Yong-Gil Kim; Soohyun Kim
Journal:  Front Immunol       Date:  2022-02-25       Impact factor: 7.561

Review 7.  Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?

Authors:  Mohamed Islam Delma
Journal:  Cureus       Date:  2020-10-12

8.  IL-32γ potentiates tumor immunity in melanoma.

Authors:  Thomas Gruber; Mirela Kremenovic; Hassan Sadozai; Nives Rombini; Lukas Baeriswyl; Fabienne Maibach; Robert L Modlin; Michel Gilliet; Diego von Werdt; Robert E Hunger; S Morteza Seyed Jafari; Giulia Parisi; Gabriel Abril-Rodriguez; Antoni Ribas; Mirjam Schenk
Journal:  JCI Insight       Date:  2020-09-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.